AUTHORS
Meera Mohan, MD, MS, Aimaz Afrough, MD2, Lei Feng, MS3, Charan Thej Reddy Vegivinti, MD4, David Berrios, M.D.5, Lorenzo Gensini, MD6, Ariel F. Grajales-Cruz, MD7, Jack Khouri, MD8, Mikhaila Rice, PharmD9, Shahzad Raza, MD10, Omar Alexis Castaneda Puglianini, MD11, Rachid Baz, MD12, Brandon Blue, MD13, Faiz Anwer, MD14, Poy Theprungsirikul, MD15, Shonali Midha, MD16, Omar Nadeem, MD17, Rahul Banerjee, MD, FACP18, Masooma Shifa Rana, MBBS19, Surbhi Sidana, MD20, Lekha Mikkilineni, MD, MA21, Saurabh Zanwar, MBBS, MD22, Saurabh Chhabra, MD, MBBS23, Hira Mian, MD24, Alissa Visram, MD, MPH25, Yi Lin Jr, MD, PhD26, Prashant Kapoor, MD27, Andrew J. Portuguese, MD28, Danai Dima, MD29, Anthony Dominick30, Kelley Julian, PharmD, BCOP31, Francesca Cottini, MD32, Ashley Rosko, MD33, Timothy O'Brien, MD34, Amrita Krishnan, MD, FACP35, Darren Pan36, Christopher Ferreri, MD37, Cindy Varga, MD38, Peter M Voorhees, MD39, Binoy Yohannan, MD40, Noa Biran, MD41, Jing Christine Ye, M.D., MSc42, Sarvari V. Yellapragada, MD43, Oren Pasvolsky, MD44, Mahmoud R. Gaballa, MD45, Daniel Schrum46, Karen Sweiss, PharmD47, Megan M Herr, PhD48, Nisha Joseph, MD49, Doris K. Hansen, MD50, Doug W. Sborov, MD, MS51, Larry D Anderson Jr, MD, PhD52, Ajai Chari, MD53, Krina Patel Jr, MD, MSc54, James A Davis, PharmD, BCOP55, Asya Varshavsky, MD56
AFFILIATIONS
2 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
8 Cleveland Clinic, Cleveland, Ohio, United States
9 Taussig Cancer Center Cleveland Clinic, Cleveland, United States
10 Taussig Cancer Center Cleveland Clinic, Cleveland, United States
11 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
12 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
13 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
14 Taussig Cancer Center Cleveland Clinic, Cleveland, United States
15 Dana-Farber Cancer Institute, Boston, United States
16 Dana-Farber Cancer Institute, Boston, United States
17 Dana-Farber Cancer Institute, Boston, United States
18 University of Washington, Seattle, United States
19 Stanford University, Palo Alto, United States
20 Stanford University, Palo Alto, United States
21 Stanford University, Palo Alto, United States
22 Mayo Clinic, Rochester, United States
23 Mayo Clinic, Phoenix, United States
24 McMaster University, Hamilton, Canada
25 McMaster University, Hamilton, Canada
26 Mayo Clinic, Rochester, United States
27 Mayo Clinic, Rochester, United States
28 University of Washington, Seattle, United States
29 University of Washington, Seattle, United States
30 Medical University of South Carolina, Charleston, United States
31 Huntsman Cancer Institute, Salt Lake City, United States
32 The Ohio State University, Columbus, United States
33 The Ohio State University, Columbus, United States
34 Seidman Cancer Center, University Hospitals Cleveland Medical Center, Saint Louis, United States
35 City of Hope Comprehensive Cancer Center, Duarte, United States
36 University of California, San Francisco, United States
37 Levine Cancer Institute, Charlotte, United States
38 Levine Cancer Institute, Charlotte, United States
39 Levine Cancer Institute, Charlotte, United States
40 University of Minnesota, Minneapolis, United States
41 Hackensack University Medical Center, New Jersey, United States
42 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
44 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
46 Duke University, Durham, United States
47 University of Illinois at Chicago, Chicago, United States
48 Roswell Park Comprehensive Cancer Center, Buffalo, United States
49 Emory University School of Medicine, Atlanta, United States
50 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
51 Huntsman Cancer Institute, Salt Lake City, United States
52 UT Southwestern, Dallas, United States
53 University of California, San Francisco, United States
54 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
55 Medical University of South Carolina, Charleston, United States
56 Fox Chase Cancer Center, Philadelphia, United States
ABSTRACT
Introduction: t(11;14) MM represents a biologically distinct subset with unique clinical and molecular features. Prior studies have suggested lower rates of deep response and minimal residual disease (MRD) negativity, together with frequent MRD resurgence; however, the relationship between response depth and long-term outcomes after bsAb remains unclear.
Methods: Within the US Myeloma Immunotherapy Consortium, we retrospectively studied relapsed/refractory MM patients treated with standard-of-care teclistamab, elranatamab, linvoseltamab, or talquetamab. High risk (HR) disease was defined as any of the following cytogenetic abnormalities or disease features: t(14;16), t(4;14), del(17p), 1q21 abnormalities, del(1p), or plasma cell leukemia (PCL). Standard risk (SR) was defined as the absence of all of the HR features.
Results: A total of 1,782 patients were included, with a median age of 69 years. The median number of prior lines of therapy was 5, with 48% of patients female and 17.5% Black. 57% of patients received a prior autologous stem cell transplant (ASCT), 87% had triple-class refractory MM, and 46% had penta-class refractory MM. 43.9% had received prior BCMA-directed bsAb and 34% a prior CAR T-cell therapy. 63% (n=1,128) received a BCMA-directed bsAb, 38% (n=654) received talquetamab. Extramedullary disease (EMD) was present in 21% of patients, and PCL in 8%. CRS of any grade occurred in 50%, ICANS in 13%, and infections in 45%.
t(11;14) was present in 17% (n=244). HR MM was present in 67% (n=1,026) and SR MM in 33% (n=513). Among patients with t(11;14), 136 (55.7%) had ≥1 HR marker [t(11;14) HR], whereas 92 (44.3%) had SR disease [t(11;14) SR]. Overall response rate (ORR) was 66.7%, with ≥VGPR achieved in 52.1% and MRD negativity in 76.2% in the entire cohort.
Compared with non-t(11;14) MM, patients with t(11;14) were older (71 vs. 68 years; p=0.005), had a longer interval from diagnosis to bsAb (72.7 vs. 67.2 months; p=0.035), and were more likely to require hemodialysis [HD] (7.7% vs. 3.9%; p=0.02). They had fewer 1q21 gains/amplifications (36% vs. 46.7%; p=0.004), with similar rates of del(17p) (27.6% vs. 24%; p=0.25). Despite these adverse baseline features, ORR, ≥VGPR, and MRD negativity were similar between the t(11;14) and non-t(11;14) groups.
Further, to determine whether cytogenetic risk modified outcomes in t(11;14) MM, patients were stratified into 4 groups: t(11;14) SR (n=92), t(11;14) HR (n=136), non-t(11;14) SR (n=396), and non-t(11;14) HR (n=791).The t(11;14) SR group was less likely to have received prior ASCT, BCMA-directed bsAb, CAR T-cell therapy, or GPRC5D-directed bsAb. The t(11;14) HR group had the highest prevalence of HD, whereas the non-t(11;14) HR group was younger and had the highest prevalence of EMD.
ORR differed across groups (61.9%, 68.6%, 65.7%, and 73.3%, respectively; p=0.028); corresponding ≥VGPR rates were 54.5%, 57%, 57.5%, and 49.3% (p=0.049), and MRD negativity rates were 42.9%, 73.3%, 85%, and 69.3% (p=0.030).
At a median follow-up of 18.6 m, median PFS and OS of the entire cohort were 10.2 and 25.7 m, respectively. Median PFS (9.8 vs 10 m; p=0.787) and OS (25.4 vs 25.7 m; p=0.869) were similar across t(11;14) and non-(11;14) MM. Median PFS for the t(11;14) SR, t(11;14) HR, non-t(11;14) SR, and non-t(11;14) HR groups were 10.6, 8.5, 15.4, and 7.9 months respectively (p=0.001); median OS was 33.9, 18.4, 33.4, and 20.9 months, respectively (p=0.004). In univariate analysis incorporating clinically relevant disease characteristics, t(11;14) alone was not associated with inferior PFS or OS, suggesting that additional HR features, rather than t(11;14) itself, drive outcomes.
Conclusion: Patients with t(11;14) SR MM disease benefit from bsAb despite lower response metrics. T(11;14) SR MM maintain excellent PFS and OS despite the lowest ORR and MRD-negativity rates among four risk groups. While coexisting HR features were associated with worse survival, outcomes in t(11;14) HR disease were similar to those in non-t(11;14) HR disease. These findings suggest that the depth of response may not fully reflect long-term benefit in this subtype and that the presence of t(11;14) may mitigate the negative impact of residual disease after bsAb therapy.
DISCLOSURES
Sarvari V. Yellapragada, MD: Binaytara Foundation - Honoraria; Pfizer - Consultancy (Includes expert testimony); Legend Biotech - Consultancy (Includes expert testimony)